All In Biotech

Drug Trial Radar · NCT03386721

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa (RO6874281), an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

256

Actual

Start

Feb 19, 2018

Primary completion

Dec 30, 2021

Study completion Dec 30, 2021

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, basket trial Phase II study to evaluate the antitumor activity of simlukafusp alfa in combination with atezolizumab in participants with advanced and/or metastatic solid tumors. Currently the focus is on participants with Head and Neck, oesophageal and cervical cancers with confirmed squamous cell carcinoma histology type.

Conditions

  • Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers

Interventions

  • simlukafusp alfaDrug

    simlukafusp alfa will be administered as per the dosage regimen mentioned in arm descriptions.

  • Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 AntibodyDrug

    Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.

  • GemcitabineDrug

    Single-agent treatment administered as per approved protocol.

  • VinorelbineDrug

    Single-agent treatment administered as per approved protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Baseline up to disease progression or study treatment discontinuation (up to 38 months)

Locations

44 sites in 15 countries. Site status is shown where the registry gives one.

  • University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Cancer Treatment Centers of America

    Newnan, Georgia

  • UZ Antwerpen

    Edegem, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Institut Bergonie

    Bordeaux, France

  • Hopital Timone Adultes; Oncologie Medicale Et Usp

    Marseille, France

  • ICM; Medecine B3

    Montpellier, France

  • Gustave Roussy Cancer Campus

    Villejuif, France

  • Universitätsklinikum Essen; Innere Klinik (Tumorforschung)

    Essen, Germany

  • Rambam Medical Center; Oncology

    Haifa, Israel

  • Auckland City Hospital; Clinical Oncology

    Auckland, New Zealand

  • Uniwersyteckie Centrum Kliniczne; Osrodek Badan Wczesnych Faz

    Gda?sk, Poland

  • Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz

    Warsaw, Poland

  • N.N.Burdenko Main Military Clinical Hospital; Oncology Dept

    Moscow, Russia

  • S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)

    Saint Petersburg, Russia

  • National University Hospital; National University Cancer Institute, Singapore (NCIS)

    Singapore, Singapore

  • National Cancer Centre; Medical Oncology

    Singapore, Singapore

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital del Mar; Servicio de Oncologia

    Barcelona, Spain

  • Hospital Univ Vall d'Hebron; Servicio de Oncologia

    Barcelona, Spain

  • Clinica Universidad de Navarra Madrid; Servicio de Oncología

    Madrid, Spain

  • Hospital Ramon y Cajal; Servicio de Oncologia

    Madrid, Spain

  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz

    Madrid, Spain

  • START Madrid. Centro Integral Oncologico Clara Campal; CIOCC

    Madrid, Spain

  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia

    Valencia, Spain

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, Spain

  • Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie

    Geneva, Switzerland

  • National Cheng Kung Uni Hospital; Dept of Hematology and Oncology

    Tainan, Taiwan

  • National Taiwan Uni Hospital; Dept of Oncology

    Taipei, Taiwan

  • Adana Baskent University Hospital; Medical Oncology

    Adana, Turkey (Türkiye)

  • Akdeniz University Medical Faculty; Medical Oncology Department

    Antalya, Turkey (Türkiye)

  • Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi

    Edirne, Turkey (Türkiye)

  • Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty; Medikal Onkoloji Departmani

    Istanbul, Turkey (Türkiye)

  • ?zmir Medical Park; Onkoloji

    Izmir, Turkey (Türkiye)

  • Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology

    Kadiköy, Turkey (Türkiye)

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.